MBX
MBX Biosciences, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$60.28-4.20%
Price as of Jul 20, 2026
MBX ownership
MBX Biosciences, Inc. Common Stock ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
4
Net (3m)
-$2.7M
Insider trades by month Buys Sells
Apr
Sep
Oct
Mar
May
Context3-month price +86.3%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 5, 2026 | Heron Patrick Jdirector, 10 percent owner: | Grant | 12,500 | $30.91 |
| Jun 5, 2026 | Ryder Stevendirector | Grant | 12,500 | $30.91 |
| Jun 5, 2026 | Hoerter Steven L.director | Grant | 12,500 | $30.91 |
| Jun 5, 2026 | Stelzer Lauriedirector | Grant | 12,500 | $30.91 |
| Jun 5, 2026 | Pescovitz Ora H.director | Grant | 12,500 | $30.91 |
| Jun 5, 2026 | Mathers Edward Tdirector | Grant | 12,500 | $30.91 |
| Jun 5, 2026 | Aynechi Tibadirector | Grant | 12,500 | $30.91 |
| May 11, 2026 | Azoulay Salomonofficer: Chief Medical Officer | Option | 55,000 | $10.46 |
| May 11, 2026 | Azoulay Salomonofficer: Chief Medical Officer | Sell | 55,000 | $38.38 |
| May 11, 2026 | Azoulay Salomonofficer: Chief Medical Officer | Option | 15,003 | $16.00 |
| May 11, 2026 | Azoulay Salomonofficer: Chief Medical Officer | Sell | 15,003 | $38.30 |
| May 8, 2026 | Azoulay Salomonofficer: Chief Medical Officer | Sell | 231 | $29.54 |
| May 8, 2026 | Hawryluk P. Kentdirector, officer: President & CEO | Sell | 607 | $29.54 |
| May 4, 2026 | Hoerter Steven L.director | Grant | 11,938 | — |
| May 4, 2026 | Hoerter Steven L.director | Grant | 74,249 | $29.78 |
| Apr 22, 2026 | Hoerter Steven L.director | Grant | 33,751 | $24.74 |
| Apr 22, 2026 | Hoerter Steven L.director | Grant | 0 | $27.08 |
| Mar 16, 2026 | Hawryluk P. Kentdirector, officer: President & CEO | Buy | 18,500 | $28.41 |
| Feb 27, 2026 | Hawryluk P. Kentdirector, officer: President & CEO | Option | 28,768 | $16.00 |
| Feb 3, 2026 | Azoulay Salomonofficer: Chief Medical Officer | Grant | 70,000 | $39.07 |
| Feb 3, 2026 | Azoulay Salomonofficer: Chief Medical Officer | Grant | 15,000 | — |
| Feb 3, 2026 | Bartram Richardofficer: Chief Financial Officer | Grant | 70,000 | $39.07 |
| Feb 3, 2026 | Bartram Richardofficer: Chief Financial Officer | Grant | 15,000 | — |
| Feb 3, 2026 | Hawryluk P. Kentdirector, officer: President & CEO | Grant | 35,250 | — |
| Feb 3, 2026 | Hawryluk P. Kentdirector, officer: President & CEO | Grant | 164,500 | $39.07 |
| Jan 22, 2026 | Stelzer Lauriedirector | Grant | 32,000 | $43.14 |
| Nov 25, 2025 | Hoerter Steven L.director | Grant | 8,000 | $27.08 |
| Nov 7, 2025 | Hoerter Steven L.director | Grant | 100,000 | $24.74 |
| Oct 28, 2025 | Hawryluk P. Kentdirector, officer: President & CEO | Option | 182,859 | $3.25 |
| Oct 21, 2025 | Hawryluk P. Kentdirector, officer: President & CEO | Buy | 20,000 | $13.64 |
Source: MBX SEC Form 4 filings, latest Jun 5, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their MBX positions over the last 6 months (SEC Form 13F).
Increased
95
New positions
78
Reduced
80
Sold out
55
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 6.7M | May 15, 2026 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | Unchanged | 6.7M | Feb 13, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 3.9M | Feb 17, 2026 |
| ORBIMED ADVISORS LLC | Reduced | 3.6M | May 15, 2026 |
| NEA MANAGEMENT COMPANY, LLC | Unchanged | 3.6M | May 15, 2026 |
| NEA MANAGEMENT COMPANY, LLC | Unchanged | 3.6M | Feb 17, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 3.3M | Feb 17, 2026 |
| DEEP TRACK CAPITAL, LP | Increased | 3.2M | Feb 13, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | Reduced | 3.2M | May 15, 2026 |
| BLACKROCK, INC. | Increased | 2.9M | May 13, 2026 |
| FMR LLC | Increased | 2.9M | May 15, 2026 |
| BLACKROCK, INC. | Increased | 2.9M | Feb 12, 2026 |
| DEEP TRACK CAPITAL, LP | Reduced | 2.8M | May 15, 2026 |
| NVP ASSOCIATES, LLC | Unchanged | 2.1M | Feb 17, 2026 |
| NVP ASSOCIATES, LLC | Unchanged | 2.1M | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.